• Citius Pharmaceuticals amended promissory note issued by Citius Oncology to align payment terms with subsidiary debt facility subordination.
• Unpaid principal of USD 3.8 million now due 91 days after Citius Oncology fully repays senior debt and terminates related loan and security agreement.
• Prior maturity triggers tied to financings were removed; cash prepayment barred before new maturity.
• Amendment adds optional conversion, subject to Citius Oncology approval, into common stock at USD 0.9 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-053916), on May 08, 2026, and is solely responsible for the information contained therein.